Cerevel Therapeutics: Parkinson's Could Be The Issue [Seeking Alpha]
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: Seeking Alpha
Concerns may be focused on the Phase 3 treatment Tavapadon for Parkinson's disease. The market expects a 75% chance of the acquisition going through, which could be too low of an expectation considering some of the facts. We'd pass, because the downside is high if anything were to go wrong, and there are unknowns here, but we see the value in this for some intrepid traders. Looking for a helping hand in the market? Members of The Value Lab get exclusive ideas and guidance to navigate any climate. Learn More » Cerevel Therapeutics ( NASDAQ: CERE ) is a company we covered prior to the acquisition announcement by AbbVie ( ABBV ). The FTC is asking for more information on the merger in a second request . Cerevel is a pre-revenue company, and there's absolutely no guarantee whatsoever that any of its treatments are going to even arrive at the market. However, we think the concerns the FTC might have are around the Phase 3 treatment Tavapadon, which is looking to enter the Parkinso
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseGlobeNewswire
- Tavapadon for Parkinson's Disease for 7MM: Market Size, Forecast, and Emerging Insights 2019-2032 - Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan [Yahoo! Finance]Yahoo! Finance
- AbbVie slips after revising guidance to reflect earnings impact [Seeking Alpha]Seeking Alpha
CERE
Earnings
- 11/1/23 - Beat
CERE
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- CERE's page on the SEC website